Summary & Overview
HCPCS J0666: Bupivacaine Liposome Injection, 1 mg
Headline: HCPCS Level II code J0666: Bupivacaine Liposome Injection, 1 mg — Billing and Clinical Context
Lead: HCPCS Level II code J0666 denotes an injectable, long‑acting formulation of bupivacaine (liposome), billed per 1 mg. The code is relevant for anesthesia, pain management, and perioperative analgesia billing across ambulatory surgery centers, hospital outpatient departments, and inpatient settings.
This code matters nationally because extended‑release local anesthetics increasingly shape perioperative pain strategies and resource utilization. Payers commonly covering services associated with this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise national view of billing practice for J0666, highlighting common payer coverage, typical sites of service, and the clinical role of bupivacaine liposome in postsurgical analgesia.
Readers will learn: key benchmarks for utilization and reimbursement trends at a national level; the clinical context for using long‑acting local anesthetic injections; and policy or coding considerations relevant to hospital and ambulatory procedural settings. Data not available in the input for specific reimbursement amounts, payer-specific coverage policies, associated ICD-10 diagnoses, and related codes is noted where applicable.
Billing Code Overview
HCPCS Level II code J0666 represents an injection formulation of bupivacaine liposome, billed per 1 mg. This code denotes a long-acting local anesthetic preparation designed for extended postoperative or procedural analgesia.
-
Service type: Injectable local anesthetic administration
-
Typical site of service: Ambulatory surgical centers, hospital inpatient and outpatient settings, and procedural clinics where regional or local anesthesia is provided
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting for a planned surgical procedure requiring prolonged local analgesia, such as unilateral total knee arthroplasty or surgical excision of a soft-tissue mass. The attending orthopedic or general surgeon coordinates with the regional anesthesia team or pain management specialist to administer J0666 (injection, bupivacaine liposome, 1 mg) as a single-shot perioperative analgesic at the surgical site or within a peripheral nerve block field. The workflow includes preoperative assessment, informed consent for local/regional anesthesia, medication preparation in pharmacy or the operating room, time‑out verification, ultrasound or landmark-guided needle placement, administration of the liposomal bupivacaine dose, and postoperative monitoring in the post anesthesia care unit (PACU) for expected analgesic effect and potential local anesthetic systemic toxicity (LAST). Documentation commonly includes indication, dose (converted from mg to total volume per product labeling), injection site, technique (e.g., single-shot infiltration, adductor canal block), laterality modifiers if applicable, and observation findings prior to discharge or transfer to inpatient floor. Typical site of service is an inpatient or outpatient hospital operating room, ambulatory surgery center, or procedural suite managed by anesthesia, surgery, or pain management teams.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service |